3 news items
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
ALKS
22 Aug 24
Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the potential therapeutic value of ALKS 2680
Alkermes plc Reports Second Quarter 2024 Financial Results
ALKS
24 Jul 24
release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
ALKS
3 Jun 24
of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning clinical development activities
- Prev
- 1
- Next